[A24-30] Elacestrant (breast cancer) – Addendum to Project A23-104
Last updated 02.05.2024
Project no.:
A24-30
Commission:
Commission awarded on 12.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Postmenopausal women, and men, with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor
after addendum now:
- Postmenopausal women with 1 prior line of endocrine therapy in the advanced/metastatic stage: added benefit not proven
- Postmenopausal women with 2 prior lines of endocrine therapy in the advanced/metastatic stage: indication of considerable added benefit
- Men: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-30_en
| Project no. | Title | Status |
|---|---|---|
| A23-104 | Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.